Literature DB >> 2211561

Trazodone dosing regimen: experience with single daily administration.

L F Fabre1.   

Abstract

Efficacy being constant, antidepressant choice is dictated by side effect profile, patient acceptance, and safety. Trazodone has been shown to be safe in overdose, and the side effect profile is mild, with sedation the most common side effect. Sleep electroencephalogram and clinical studies have shown trazodone effective in improving sleep in normal subjects, insomniac patients, and patients with major depression. Tolerance and rapid eye movement rebound on discontinuation do not occur. The 3- to 9-hour half-life of trazodone and its pharmacokinetics favors a dose weighted at bedtime. Studies comparing multiple daytime dosing to single dosing at bedtime have shown equal efficacy in relieving depression. At treatment onset, a single nighttime dose is more productive of sleep with less daytime drowsiness. These differences between single nighttime dosing and multiple daily dosing disappear with continued administration. Geriatric patients respond similarly. Trazodone is best dosed at 150 mg given predominantly (but not necessarily all) at bedtime and increased as needed to 200 to 300 mg for full antidepressant efficacy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2211561

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

1.  Treatment of sleep disturbance in alcohol recovery: a national survey of addiction medicine physicians.

Authors:  Peter D Friedmann; Debra S Herman; Shelby Freedman; Stephenie C Lemon; Susan Ramsey; Michael D Stein
Journal:  J Addict Dis       Date:  2003

2.  Inhibition of Kv4.3 potassium channels by trazodone.

Authors:  Yun Ju Chae; Jin-Sung Choi; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-25       Impact factor: 3.000

3.  Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial.

Authors:  Peter D Friedmann; Jennifer S Rose; Robert Swift; Robert L Stout; Richard P Millman; Michael D Stein
Journal:  Alcohol Clin Exp Res       Date:  2008-07-08       Impact factor: 3.455

Review 4.  Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.

Authors:  M Haria; A Fitton; D McTavish
Journal:  Drugs Aging       Date:  1994-04       Impact factor: 3.923

Review 5.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

6.  Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study.

Authors:  David V Sheehan; Harry A Croft; E Roderich Gossen; Randy J Levitt; Claire Brullé; Sylvie Bouchard; Anna Rozova
Journal:  Psychiatry (Edgmont)       Date:  2009-05

7.  Chronic dosing with mirtazapine does not produce sedation in rats.

Authors:  Alberto Salazar-Juárez; Susana Barbosa-Méndez; Paola Merino-Reyes; Maura Matus-Ortega; Jorge A Hernández-Calderón; Benito Antón
Journal:  Braz J Psychiatry       Date:  2017-03-23       Impact factor: 2.697

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.